Centerpoint Advisors’s Lipocine LPCN Stock Holding History

Centerpoint Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-353	Closed	-$21K	–	253
2017 Q4	$21K	Buy	+353	New	+$22K	0.02%	114

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Centerpoint Advisors's LPCN Position: Q1 2018 in Review

Centerpoint Advisors sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 353 shares — an estimated $21K sold.

Centerpoint Advisors first reported a position in LPCN in Q4 2017 and held it in 1 quarter. The position peaked at $21K in Q4 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

Centerpoint Advisors reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
Centerpoint Advisors sold 353 Lipocine shares in Q1 2018, an estimated $21K.
Centerpoint Advisors first reported a position in Lipocine in Q4 2017 and held it in 1 quarter.
Centerpoint Advisors's Lipocine position peaked at $21K in Q4 2017.
27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Centerpoint Advisors's 13F filing for Q1 2018, filed 9 May 2018.